Deeti Pithadia, MD, FAAD
Speaker
Pediatric Dermatologist, Cleveland Clinic
FACIAL ANGIOFIBROMAS IN TUBEROUS SCLEROSIS COMPLEX
Recognition, Treatment and Case-Based Management
Release Date: November 17, 2026 · Expiration Date: November 17, 2029
Register Here for Free
Activity Overview
Facial angiofibroma is a common and distinctive manifestation of tuberous sclerosis complex (TSC). Recognizing these lesions
is important because, in some patients, they may be an early clue to previously undiagnosed TSC. For patients with an
established diagnosis, however, questions about how and when to treat facial angiofibroma can be complex. This program will
provide practical guidance on treatment options and management considerations through expert discussion and case-based
examples.
Program Agenda
| Time (ET) | Session |
|---|---|
| 8:00–8:03 PM | Welcome and speaker introductions Joyce Teng, MD, PhD |
| 8:03–8:33 PM | Tuberous Sclerosis Complex: A Dermatologist's Guide to Cutaneous Findings and Facial Angiofibroma Management Deeti Pithadia, MD, FAAD |
| 8:33–8:55 PM | Tuberous Sclerosis Complex and Case Studies Dawn Eichenfield, MD, PhD, FAAD |
| 8:55–9:00 PM | Q&A Session |
Meet the Faculty
Dawn Eichenfield, MD, PhD, FAAD
Speaker
Pediatric Dermatologist, Rady Children's Hospital–San Diego
Joyce Teng, MD, PhD
Moderator
Professor of Dermatology, Stanford Medicine
Program Description
CME Webinar to Address Recognition and Management of Facial Angiofibroma in Tuberous Sclerosis Complex (TSC)
A free, live continuing medical education (CME) webinar on Tuesday, November 17, 2026, at 8 p.m. ET, will explore the recognition and management of facial angiofibroma, a common manifestation of tuberous sclerosis complex (TSC), through expert presentations and case-based discussion.
Titled Facial Angiofibroma in Tuberous Sclerosis Complex: Recognition, Treatment and Case-Based Management, the 60-minute program will feature two pediatric dermatologists: Deeti Pithadia, MD, FAAD, of Cleveland Clinic, and Dawn Eichenfield, MD, PhD, FAAD, of Rady Children's Hospital–San Diego.
Facial angiofibromas occur in approximately 75% to 80% of patients with TSC. Recognizing these lesions is important because they may be an early indication of previously undiagnosed TSC. For patients with an established diagnosis, treatment decisions can involve a range of medical and procedural options, as well as considerations related to age and other individual patient factors.
Dr. Pithadia will present Tuberous Sclerosis Complex: A Dermatologist's Guide to Cutaneous Findings and Facial Angiofibroma Management, covering the clinical presentation of facial angiofibroma and factors that influence treatment decisions. Dr. Eichenfield will discuss TSC and present two case-based scenarios illustrating treatment considerations.
Joyce Teng, MD, PhD, professor of dermatology at Stanford Medicine, will moderate the program, introduce the speakers, and lead the closing question-and-answer session.
Participants can earn 1.0 AMA PRA Category 1 Credit. The activity is provided by AKH Inc., Advancing Knowledge in Healthcare, and supported by an independent medical education grant from Nobelpharma America.
Target Audience
This activity is designed for an audience of Dermatologists, Neurologists, Dermatology Nurses, Physician Assistants, Pediatric Physicians, Pharmacists, Pharmacy technicians and other healthcare professionals.
Learning Objectives
Upon completion of the educational activity, participants should be able to:
• Recognizing facial angiofibromas and their clinical presentation
• Understanding factors that influence treatment decisions
Criteria for Success
To obtain credit, you must complete the activity evaluation and claim credit based on your attendance. The Certificate of Completion is immediately available for download after submitting your evaluation. It will remain in your profile transcript for future retrieval if needed. It can be found under My Account > My Activities > Completed Activities.
Unable to attend live?
The recorded program is planned to remain available for viewing and eligible CME/CE credit through November 17, 2029, subject to the activity’s credit requirements.
If you have any questions, please contact Bassem at ph. (703) 402-0125.
Instructions for claiming CME/CE credit:
• To claim your CE credit, use the AKH link or QR code provided below.
• Click Register/Take Course > Click Register (or Login if you've already created an account).
• Click Get Started to continue to the evaluation, claim credit, and download your Certificate of Completion.
Your certificate will remain available anytime under My Account > My Activities.
Please claim your credit within 30 days of this activity.
Claim Your CME Credit
Please claim your CME education credit for:
FACIAL ANGIOFIBROMAS IN TUBEROUS SCLEROSIS COMPLEX
Recognition, Treatment and Case-Based Management
CE credit provided by AKH Inc., Advancing Knowledge in Healthcare.
In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and Kikaku America International. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
AKH Inc., Advancing Knowledge in Healthcare designates this live activity a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
Credit being awarded: 1.0 ANCC contact hours
Pharmacists
AKH Inc., Advancing Knowledge in Healthcare designates this continuing education activity for 1.0 contact hours.
Physician Associate
AKH Inc., Advancing Knowledge in Healthcare has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
Nurse Practitioners
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and Kikaku America International. AKH Inc., Advancing Knowledge in Healthcare is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030803. This activity is approved for 1.0 contact hour(s) (which includes 0.5 hour(s) of pharmacology).
Commercial Support
This activity is supported by an independent medical education grant from Nobelpharma America.
DISCLOSURES
| Name | Relationship | Commercial Interest |
|---|---|---|
| Dawn Eichenfield, MD, PhD (faculty) | Consultant | Apogee; Arcutis; Beiersdorf; Chiesi; Eli Lilly and Company; Galderma; Incyte; Nobelpharma; Ortho Dermatologics; Palvella; Pelthos; Regeneron; Sanofi; Verrica |
| Speaker | Galderma; Sanofi; Verrica | |
| Researcher | Eli Lilly and Company; Incyte; Johnson and Johnson | |
| Deeti Pithadia, MD (faculty) | N/A | Nothing to disclose |
| Peter Sonnenreich, President & CEO, Kikaku America International (committee member/planner) | N/A | Nothing to disclose |
| Joyce Teng, MD, PhD (moderator) | N/A | Nothing to disclose |
| Dorothy Caputo, MA, BSN, RN - President, AKH Inc., Advancing Knowledge in Healthcare (planner/reviewer) | N/A | Nothing to disclose |
| Bernadette Makar, MSN, APRN-BC, NP-C (planner/reviewer) | N/A | Nothing to disclose |
| All of the relevant financial relationships listed for these individuals have been mitigated. | ||
Disclosures
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.
Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participants misunderstanding of the content. If you would like to opt out from future communications from AKH please send an email to optout@akhcme.com with your information with "Opt Out" in the subject line.